GEM00220 / Northern Therap - LARVOL DELTA

The AMETHYST (Advanced Mesenchymal Enhanced cell THerapY for SepTic) Trial: A First-in-Human, Dose Escalation Phase 1 Safety Trial of Genetically Enhanced MSCs (GEM00220) Appeared Safe and Well Tolerated in Patients with Septic Shock (ASGCT 2024) - "Infusing cryopreserved GEM00220, up to 300 million cells, into patients with severe septic shock seemed safe and feasible. Further work is needed to establish the efficacy of GEM00220 in this patient population"

Clinical • Late-breaking abstract • Metastases • P1 data • Cardiovascular • Septic Shock

AMETHYST: Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients (clinicaltrials.gov) - P1 | N=11 | Terminated | Sponsor: Northern Therapeutics | Active, not recruiting ➔ Terminated; Funding Decision

Metastases • Trial termination • Septic Shock

AMETHYST: Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients (clinicaltrials.gov) - P1 | N=11 | Active, not recruiting | Sponsor: Northern Therapeutics | Recruiting ➔ Active, not recruiting | N=21 ➔ 11

Enrollment change • Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Septic Shock

AMETHYST: Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Northern Therapeutics | Trial completion date: Nov 2022 ➔ Aug 2024 | Trial primary completion date: Dec 2021 ➔ Sep 2023

Trial completion date • Trial primary completion date • Septic Shock

AMETHYST: Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients (clinicaltrials.gov) - P1; N=9; Recruiting; Sponsor: Northern Therapeutics; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Septic Shock

AMETHYST: Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients (clinicaltrials.gov) - P1; N=9; Not yet recruiting; Sponsor: Northern Therapeutics

Clinical • New P1 trial • Septic Shock